5-MAPB

From PsychonautWiki
Jump to: navigation, search
Proofread.png

This article requires proofreading.

As such, it may contain incorrect grammar, spelling, or punctuation.

Summary sheet: 5-MAPB
5-MAPB
5-MAPB.svg
Chemical Nomenclature
Common names 5-MAPB
Substitutive name 5-(2-methylaminopropyl)benzofuran
Systematic name (1-(benzofuran-5-yl)-N-methylpropan-2-amine)
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold Common Heavy
20 - 40 - 60 - 80 - 100 mg
Light Strong
Threshold 20 - 40 mg
Light 40 - 60 mg
Common 60 - 80 mg
Strong 80 - 100 mg
Heavy 100 mg +
Duration
Total 5 - 8 hours
Onset 20 - 60 minutes
Come up 45 - 90 minutes
Peak 2 - 4 hours
Offset 1.5 - 3 hours
After effects 6 - 48 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

5-(2-methylaminopropyl)benzofuran (abbreviated 5-MAPB) is a synthetic entactogen of the substituted benzofuran class of chemicals, which are known to produce euphoric, entactogenic, stimulating and mildly hallucinogenic effects. These include such MDA-inspired substances as 5-APB, 6-APB and 5-EAPB, among others. 5-MAPB is the N-methylated form of 5-APB, analogously to how MDMA is the N-methylated form of MDA.

This compound is known for its stimulating, euphoric and entactogenic effects that is capable of acting a quasi-substitute for MDMA proper, which has resulted in its rise in popularity as a research chemical that is easily accessible through the use of online vendors. It has been sold as a designer drug since 2010.[1]

5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 10% more potent by mass so doses should be adjusted accordingly.[Controversial]

Chemistry

5-(2-methylaminopropyl)benzofuran, or 5-MAPB, is a substituted benzofuran and phenethylamine. It is comprised of an N-methylated ethylamine chain and a furan ring attached to a central benzene ring. It can also be classified as a derivative of methamphetamine because the N-methylated ethylamine chain is alpha methylated in an analagous manner. Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. The oxygen atom in the furan ring is placed at the 5 position, which generally constitutes more stimulating effects than when the oxygen is placed at the 6 position, which usually renders it more psychedelic in effect.

Pharmacology

5-MAPB is a triple reuptake inhibitor for the monoamines norepinephrine, dopamine and serotonin as well as being an agonist for the 5-HT2A and 5-HT2B receptors.[2][3] It has also been speculated that 5-MAPB acts as a releasing agent for the previously mentioned neurotransmitters.

As a result, releasing agents such as 5-MAPB may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in stimulating and euphoric effects.

Subjective effects

Metacogghjgjvghnition.png
This subjective effect breakdown is a stub.

As such, it may contain incomplete or wrong information and is still in progress.

You can help by expanding it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

After effects
Aftereffects (3).svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 5-MAPB use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 5-MAPB has very little history of human usage. Anecdotal evidence from people who have tried 5-MAPB within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

5-MAPB's notable agonism at the serotonin-2b (5-HT2b) receptor (which has been associated with cardiovalvulopathy) suggests that it would be cardiotoxic with long-term use, as seen in other 5-HT2B agonists such as fenfluramine and MDMA.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other entactogenic stimulants, the chronic use of 5-MAPB can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 5-MAPB develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 5-MAPB presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 5-MAPB all stimulants will have a reduced effect.

Psychosis

Main article: Stimulant psychosis

Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. Psychosis very rarely arises from therapeutic use.

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Serotonin syndrome risk

Combinations in the list below may increase the amount of neurotransmitters such as serotonin and dopamine to dangerous or even fatal levels.

Legal issues

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United Kingdom: 5-MAPB is a Class B drug.
  • United States: 5-MAPB could be considered an analogue of MDA and therefore would be covered under the Federal Analogue Act if intended for human consumption.

See also

External links

References

  1. EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | http://www.emcdda.europa.eu/publications/implementation-reports/2010
  2. The effects of benzofury (5-MAPB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24012617?dopt=Abstract
  3. Neurochemical profiles of some novel psychoactive substances (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299912010114
  4. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  5. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210